Ambient tonicity and intestinal cytochrome CYP3A

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 8, 2010, Pages 883-893

  Chuang, Andrew I ^a   Ito, Shinya ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

CYP3A; First pass metabolism; NFAT5 TonEBP; Osmolality; P450 drug metabolism enzymes

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYCLOSPORIN; CYTOCHROME P450 3A; HYPERTONIC SOLUTION; MIDAZOLAM; NIFEDIPINE; QUINIDINE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT5; UNCLASSIFIED DRUG; VERAPAMIL; SALT INTAKE;

DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME SUBSTRATE; GASTROINTESTINAL TRACT; GENE EXPRESSION; HIGH SODIUM INTAKE; HUMAN; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; METABOLITE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSMOLALITY; OSMOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION INITIATION; ANIMAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; INTESTINE MUCOSA; METABOLISM; OSMOLARITY; PHARMACOLOGY; POSTPRANDIAL STATE; SALT INTAKE;

ANIMALS; CYTOCHROME P-450 CYP3A; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTESTINAL MUCOSA; NFATC TRANSCRIPTION FACTORS; OSMOLAR CONCENTRATION; POSTPRANDIAL PERIOD; SODIUM CHLORIDE, DIETARY; TRANSCRIPTION, GENETIC;

EID: 77954836528     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425251003781912     Document Type: Review

References (100)

1. Isin EM, Guengerich FP. Substrate binding to cytochromes P450. Anal Bioanal Chem 2008;392:1019-1030
2. Lamb DC, Waterman MR, Kelly SL, Guengerich FP. Cytochromes P450 and drug discovery. Curr Opin Biotechnol 2007;18:504-512
3. Guengerich FP. Mechanisms of cytochrome P450 substrate oxidation: minireview. J Biochem Mol Toxicol 2007;21:163-168
4. Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715
5. Ma Q, Lu AY. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007;35:1009-1016
6. Yamada H, Ishii Y, Yamamoto M, Oguri K. Induction of the hepatic cytochrome P450 2B subfamily by xenobiotics: research history, evolutionary aspect, relation to tumorigenesis and mechanism. Curr Drug Metab 2006;7:397-409
7. Raunio H, Rautio A, Pelkonen O. The CYP2A subfamily: function, expression and genetic polymorphism. IARC Sci Publ 1999;148:197-207
8. Kessova I, Cederbaum AI. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 2003;3:509-518
9. Martinez-Jimenez CP, Jover R, Donato MT, et al. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 2007;8:185-194
10. Westlind A, Malmebo S, Johansson I, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001;182:1349-1355
11. Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2008;97:1775-1800
12. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009;61:541-558
13. Kolars JC, Schmiedlin-Pen P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-1878
14. McKinnon RA, Burgess WM, Hall PM, et al. Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995;36:259-267
15. Stanley LA, Horsburgh BC, Ross J, et al. PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 2006;38:515-597
16. Kolar JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporine by the gut. Lancet 1991;14:1488-1490
17. Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-471
18. Holtbecker N, Fromm MF, Kroemer HK, et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24:1121-1123
19. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal protein expression. J Clin Invest 1997;99:2545-2553
20. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24:796-801
21. Bailey DG, Malcon J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101-110
22. Satsu H, Hiura Y, Mochizuki K, et al. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 2008;56:5366-5373
23. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 2003;1619:243-253
24. Fukumori S, Murata T, Taguchi M, Hashimoto Y. Rapid and drastic induction of CYP3A4 mRNA expression via vitamin D receptor in human intestinal LS180 cells. Drug Metab Pharmacokinet 2007;22:377-381
25. Wang K, Chen S, Xie W, Wang YJ. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol 2008;75:2204-2213
26. Tegude H, Schnabel A, Zanger UM, et al. Molecular mechanism of basal CYP3A regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine. Drug Metab Dispos 2007;35:946-954
27. Sheppard KE. Nuclear receptors. II. Intestinal corticosteroid receptors. Am J Physiol Gastrointest Liver Physiol 2002;282:G742-746
28. Wisely GB, Miller AB, Davis RG, et al. Hepatocytes nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure 2002;10:1225-1234
29. Kosuge K, Chuang AI, Uematsu S, et al. Discovery of osmosensitive transcriptional regulation of human cytochrome P450 3As by the tonicity-responsive enhancer binding protein (nuclear factor of activated T cells 5). Mol Pharmacol 2007;72:826-837
30. Go WY, Liu X, Roti MA, et al. NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. Proc Natl Acad Sci USA 2004;101:10673-10678
31. Kultz D, Chakravavarty D. Hyperosmolality in the form of elevated NaCl but not urea causes DNA damage in murine kidney cells. Proc Natl Acad Sci USA 2001;98:1999-2004
32. Dmitrieva NI, Cai Q, Burg MB. Cells adapted to high NaCl have many DNA breaks and impaired DNA repair on in cell culture and in vivo. Proc Natl Acad Sci USA 2004;101:2317-2322
33. Dmitrieva NI, Michea LF, Burg M. P53 protects renal inner medullary cells from hypertonicity stress by restricting DNA replication. Am J Physiol Renal Physiol 2001;281:F522-30
34. Dmitrieva NI, Michea LF, Rocha GM, Burg M. Cell cycle delay and apoptosis in response to osmotic stress. Comp Biochem Phyisol A Mol Integr Physiol 2001;130:411-420
35. Copp J, Wiley S, Ward MW, Van Der Geer P. Hypertonic shock inhibits growth factor receptor signaling, induces caspase 3 activation and causes reversible fragmentation of the mitochondria network. Am J Physiol Cell Physiol 2005;288:C403-15
36. Di Ciano C, Nie Z, Szaszi K, et al. Osmotic stress-induced remodeling of the cortical cytoskeleton. Am J Physiol Cell Physiol 2002;283:C850-65
37. Morley SJ, Naegele S. Phosphorylation of eukaryotic initiation factor (eIF) 4E is not required for de novo protein synthesis following recovery from hypertonic stress in human kidney cells. J Biol Chem 2002;277:32855-32859
38. Zhang Z, Dmitrieva NI, Park HK, et al. High urea and NaCl carbonylate proteins in renal cells in culture and in vivo, and high urea causes 8-oxoguanine lesions in their DNA. Proc Natl Acad Sci USA 2004;101:9491-9496
39. Burg MB, Ferrais JD, Dmitrieva NI. Cellular response to hyperosmotic stresses. Physiol Rev 2007;87:1441-1474
40. Ho SN. Intracellular water homeostasis and the mammalian cellular osmotic stress response. J Cell Physiol 2006;206:9-15
41. Lang F, Busch GL, Ritter M, et al. Functional significance of cell volume regulatory mechanisms. Physiol Rev 1998;78:247-306 (Pubitemid 28070981)
42. Garner MM, Burg MB. Macromolecular crowding and confinement in cells exposed to hypertonicity. Am J Physiol 1994;266:C877-892
43. Street TO, Bolen DW, Rose GD. A molecular mechanism for osmolyte-induced protein stability. Proc Natl Acad Sci USA 2006;103:13997-14002
44. Ko BC, Ruepp B, Bohren KM, et al. Identification and characterization of multiple osmotic response sequence in the human aldose reductase gene. J Biol Chem 1997;272:16431-16437
45. Rims JS, Atta MG, Dahl SC, et al. Transcription of the sodium/myo-inositol cotransporter gene is regulated by multiple tonicity-responsive enhancers spread over 50 kilobase pairs in the 5¢-flanking region. J Biol Chem 1998;273:20615-20621
46. Miyakawa H, Woo SK, Chen CP, et al. Cis- and trans-acting regulating transcription of the BGT1 gene in response to hypertonicity. Am J Physiol 1998;274:F753-761
47. Ito T, Fujio Y, Hirata M, et al. Expression of taurine transporter is regulated through the TonE (tonicity-responsive element)/TonEBP (TonE-binding protein) pathway and contributes to cytoprotection in HepG2 cells. Biochem J 2004;382:177-182
48. Woo SK, Lee SD, Na KY, et al. TonEBP/NFAT5 stimulates transcription of HSP70 in response to hypertonicity. Mol Cell Biol 2002;22:5753-5760
49. Lopez-Rodriguez C, Aramburu J, Jin L, et al. Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity 2001;15:47-58
50. Miyakawa H, Woo SK, Dahl SC, et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc Natl Acad Sci USA 1999;96:2538-2542
51. Ko BC, Lam AK, Kapus A, et al. Fyn and p38 signaling are both required for maximal hypertonic activation of the osmotic response element-binding protein/tonicity-responsive enhancer-binding protein (OREBP/TonEBP). J Biol Chem 2002;277:46085-46092
52. Ferrais JD, Persaud P, Williams CK, et al. cAMP-independent role of PKA in tonicity-induced transactivation of tonicity-responsive enhancer/osmotic response element-binding protein. Proc Natl Acad Sci USA 2002;99:16800-16805
53. Irarrazabal CE, Liu JC, Burg MB, Ferraris JD. ATM, a DNA damage-inducible kinase, contributes to activation by high NaCl of the transcription factor TonEBP/OREBP. Proc Natl Acad Sci USA 2004;101:8809-8814
54. Lee SD, Woo SK, Kwon HM. Dimerization is required for phosphorylation and DNA binding of TonEBP/NFAT5. Biochem Biophys Res Commun 2002;294:968-975
55. Tong EH, Guo KK, Huang AL, et al. Regulation of nucleocytoplasmic trafficking of transcription factor OREBP/TonEBP/NFAT5. J Biol Chem 2006;81:23870-23879
56. Maouyo D, Kim JY, Lee SD, et al. Mouse TonEBP-NFAT5: expression in early development and alternative splicing. Am J Physiol Renal Physiol 2002;282:F802-809
57. Trama J, Lu Q, Hawley RG, Ho SN. The NFAT-related proteinNFATL1 (TonEBP/NFAT5) is induced upon T cell activation in a calcineurin-dependent manner. J Immunol 2000;165:4884-4894
58. Navarro P, Chiong M, Volkwein K, et al. Osmotically-induced genes are controlled by the transcription factor TonEBP in cultured cardiomyocytes. Biochem Biophys Res Commun 2008;372:326-330
59. Lee JH, Kim M, Im YS, et al. NFAT5 induction and its role in hyperosmolar stressed human limbal epithelial cells. Invest Ophthalmol Vis Sci 2008;49:1827-1835
60. Morancho B, Minguillon J, Molkentin JD, et al. Analysis of the transcriptional activity of endogenous NFAT5 in primary cells using transgenic NFAT-luciferase reporter mice. BMC Mol Biol 2008;9:13
61. Ito T, Asakura K, Tougou K, et al. Regulation of cytochrome P450 2E1 under hypertonic environment through TonEBP in human hepatocytes. Mol Pharmacol 2007;72:173-181
62. Aramburu J, Drews-Elger K, Estrada-Gelonch A, et al. Regulation of the hypertonic stress response and other cellular functions by the Rel-like transcription factor NFAT5. Biochem Pharmacol 2006;72:1597-1604
63. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism, and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1:446-471
64. Kong F, Singh RP. Disintegration of solid foods in human stomach. J Food Sci 2008;73:R67-80
65. Kalantzi L, Goumas K, Kalioras V, et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/ bioequivalence studies. Pharm Res 2006;23:165-176
66. Gisolfi CV, Summers RW, Lambert GP, Xia T. Effect of beverage osmolality on intestinal fluid absorption during exercise. J Appl Physiol 1998;85:1941-1948
67. Lindahl A, Ungel AL, Knutson L, Lennernas H. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 1997;14:497-502
68. Kalantzi L, Persson E, Polentarutti B, et al. Canine intestinal contents vs. stimulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 2006;23:1373-1381
69. Pihl L, Wilander E, Nylander O. Comparative study of the effects of luminal hypotonicity on mucosal permeability in rat upper gastrointestinal tract. Acta Physiol (Oxf) 2008;193:67-78
70. Hoffmann ML, DenBleyker M, Smith JC, Stricker EM. Inhibition of thirst when dehydrated rats drink water or saline. Am J Physiol Regul Integr Comp Physiol 2006;290:R1199-1207
71. Nishinaka D, Kishino F, Matuura A. Water and electrolyte absorption from hypotonic oral rehydration solution in rat small intestine and colon. Pediatr Int 2004;46:315-321 (Pubitemid 38756970)
72. Bachmann O, Riederer B, Rossmann H, et al. The Na+/H+ exchanger isoform 2 is the predominant NHE isoform in murine colonic crypts and its lack causes NHE3 upregulation. Am J Physiol Gastrointest Liver Physiol 2004;287:G125-133
73. Mignen O, Le Gall C, Harvey BJ, Thomas S. Volume regulation following hypotonic shock in isolated crypts of mouse distal colon. J Physiol 1999;515:501-510
74. Osaka T, Kobayashi A, Inoue S. Therogenesis induced by osmotic stimulation of the intestines in the rat. J Physiol 2001;532:261-269
75. Martignoni M, Groothuis G, de Kanter R. Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos 2006;34:1047-1054
76. Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 2004;14:1-18
77. Williams ET, Rodin AS, Strobel HW. Defining relationships between the known members of the cytochrome P450 3A subfamily, including five putative chimpanzee members. Mol Phylogenet Evol 2004;33:300-308
78. Darbar D, Dell'Orto S, M€orike K, et al. Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 1997;61:292-300
79. Brain WR, Sari MA, Iwasaki M, et al. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 1990;29:11280-11292
80. Caporaso NE, Shaw GL. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine. Arch Intern Med 1991;151:1985-1992
81. Darbar D, Fromm MF, Dell'Orto S, et al. Modulation by dietary salt of verapamil disposition in humans. Circulation 1998;98:2702-2708
82. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer W. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 1999;47:545-552
83. Kang HJ, Song IS, Lee SS, et al. Effects of dietary salt on the expression of drug transporters cytochrome P4503a, and nuclear receptors in rats. Xenobiotica 2008;38:147-155
84. Takara K, Ohnishi N, Horibe S, Yokoyama T. Expression profiles of drug-metabolizing enzymes CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNA in rat small intestine. Drug Metab Dispos 2003;31:1253-1339
85. Liu J, Callahan SM, Brunner LJ. Effects of sodium alternations on hepatic cytochrome P450 3A2 and 2C11 and renal function in rats. Drug Dev Ind Pharm 2003;29:767-775
86. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A expression. Nat Genet 2001;27:383-391
87. Fujita T. Aldosterone in salt-sensitive hypertension and metabolic syndrome. J Mol Med 2008;86:729-734
88. Biller BM, Grossman AB, Steward PM, et al. Treatment of adrenocorticotrophin-dependent Cushing's syndrome: a consensus statement. J Clinc Endocrinol Metab 2008;93:2454-2462
89. Haehner BD, Gorski JC, Vandenbranden M, et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996;50:52-59
90. Ghosh S, Grogan WM, Basu A, Watlington C. Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. Biochim Biophys Acta 1993;1182:152-156
91. Whiteworth JA, Williamson PM, Mangos G, Kelly JJ. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005;1:291-299
92. Grogan WM, Philips VM, Schuetz EG, et al. Corticosterone 6 beta-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450. Am J Physiol. 1990;258:C480-8
93. Duncan RL, Grogan WM, Kramer LB, Watlington CO. Corticosterone's metabolite is an agonist for Na+ transport stimulation in A6 cells. Am J Physiol 1998;255:F736-48
94. Galteau MM, Shamsa F. Urinary 6betahydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003;59:713-733
95. Thompson EE, Kuttab-Boulos H, Witonsky D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004;75:1059-1069
96. Busi F, Cresteil T. CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol Pharmacol 2005;68:808-815
97. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in health adults. J Appl Physiol 2003;95:1297-1300
98. Thompson EE, Kuttab-Boulous H, Yang L, et al. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006;6:105-114
99. Bochud M, Eap CB, Elston RC, et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006;24:923-929
100. Cheung C, Yu AM, Cheng CS, et al. Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther 2006;316:1328-1334